Skeletal disorders

New ArthritisPower Data Highlights Contradiction Between Patients Expressing Satisfaction with Treatment Despite Breakthrough Symptoms

Retrieved on: 
Friday, June 4, 2021
General Health, Health, Science, Pharmaceutical, Research, Medical specialties, Rheumatology, Clinical medicine, Medicine, Autoimmune diseases, Psoriasis, Arthritis, Psoriatic arthritis, Skeletal disorders, Enthesitis

Treatment satisfaction was lower for participants experiencing wear-off compared to those without wear-off.

Key Points: 
  • Treatment satisfaction was lower for participants experiencing wear-off compared to those without wear-off.
  • Future research needs to address how patients manage breakthrough symptoms in axSpA and what prompts them to seek a new treatment strategy.
  • In the poster titled, Real-world patient experience and treatment preferences in patients with psoriatic arthritis (PsA), a cross-sectional, web-based ArthritisPower survey evaluated disease burden and treatment preferences in people living with PsA (n=332).
  • Patients reported joint pain-related symptoms (e.g., joint, lower back or spine, and enthesitis-related pain) as the most bothersome, while the least bothersome symptoms were psoriasis-related.

cbdMD Therapeutics Announces Launch Of Animal Health Study In Collaboration With Colorado State University’s Veterinary Program

Retrieved on: 
Thursday, June 3, 2021
Alternative medicine, Education, Retail, Health, Specialty, University, Veterinary, Skeletal disorders, Medical specialties, Clinical medicine, Medicine, Arthritis, Osteoarthritis, Aging-associated diseases, Rheumatology, Dog

The results from this study will provide validating data on the efficacy of the Company's products in reducing pain and improving joint mobility in dogs.

Key Points: 
  • The results from this study will provide validating data on the efficacy of the Company's products in reducing pain and improving joint mobility in dogs.
  • The Company expects the full study to be complete by the Spring 2022. cbdMDs Paw CBD brand is one of the leading CBD animal health brands in the U.S.
  • It has been estimated that one in five dogs are diagnosed with osteoarthritis in their lifetime.
  • With almost 1 billion dogs globally and over 75 million in the US, osteoarthritis effects millions of our loved ones.

New data presented at Virtual EULAR 2021 Congress by AKL Research and Development demonstrate its investigational osteoarthritis drug APPA reduces senescence and reactive oxygen species production

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Medical specialties, Skeletal disorders, Senescence, Arthritis, Cellular processes, Cellular senescence, Senescence-associated secretory phenotype, Chondrocyte, Autophagy, Inflammatory cytokine

Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.

Key Points: 
  • Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.
  • In chondrocytes, senescence-associated secretory phenotype factors, such as pro-inflammatory cytokines and extracellular matrix degrading enzymes, can contribute to the development and progression of OA[2][3].
  • This research builds on previous work from INBIC and other laboratories that showed APPA modifies a number of pathways involved in the development of OA.
  • [3]Benderdour M, Martel-Pelletier J, Pelletier JP, Kapoor M, Zunzunegui MV, Fahmi H. Cellular Aging, Senescence and Autophagy Processes in Osteoarthritis.

New data presented at Virtual EULAR 2021 Congress by AKL Research and Development demonstrate its investigational osteoarthritis drug APPA reduces senescence and reactive oxygen species production

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Medical specialties, Skeletal disorders, Senescence, Arthritis, Cellular processes, Cellular senescence, Senescence-associated secretory phenotype, Chondrocyte, Autophagy, Inflammatory cytokine

Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.

Key Points: 
  • Findings from the study indicate its investigational oral osteoarthritis (OA) drug APPA can reduce reactive oxygen species (ROS) production and senescence of human articular chondrocytes, both indicators associated with OA pathogenesis.
  • In chondrocytes, senescence-associated secretory phenotype factors, such as pro-inflammatory cytokines and extracellular matrix degrading enzymes, can contribute to the development and progression of OA[2][3].
  • This research builds on previous work from INBIC and other laboratories that showed APPA modifies a number of pathways involved in the development of OA.
  • [3]Benderdour M, Martel-Pelletier J, Pelletier JP, Kapoor M, Zunzunegui MV, Fahmi H. Cellular Aging, Senescence and Autophagy Processes in Osteoarthritis.

First-Ever Virtual ARThritis Soirée Sees Big Success

Retrieved on: 
Friday, May 28, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Aging-associated diseases, Skeletal disorders, Syndromes, Arthritis, Sjögren syndrome

"Arthritis is the leading cause of work disability in Canada and can cause serious, life-threatening complications," said Dr. Diane Lacaille , Arthritis Research Canada's Scientific Director.

Key Points: 
  • "Arthritis is the leading cause of work disability in Canada and can cause serious, life-threatening complications," said Dr. Diane Lacaille , Arthritis Research Canada's Scientific Director.
  • "We are extremely grateful to our sponsors, performers, guests and donors for participating in the virtual ARThritis Soire to help vital arthritis research continue."
  • Arthritis Research Canada would like to thank Macdonald Realty and Macdonald Commercial for supporting the ARThritis Soire as Presenting Sponsor for three consecutive years.
  • "Arthritis is an invisible and misunderstood disease and the ARThritis Soire is an important opportunity for raising awareness and funds to support arthritis research and bring change to the way people live with pain and disability."

Treace Medical Concepts Reports First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, May 25, 2021
Foot diseases, Skeletal disorders, Geography of Florida, Bunion, Valgus, Ponte Vedra Beach, Florida, Florida

PONTE VEDRA, Fla., May 25, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2021.

Key Points: 
  • PONTE VEDRA, Fla., May 25, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2021.
  • Gross margin increased to 82.2% in the first quarter of 2021, compared to 78.8% in the first quarter of 2020.
  • Treace Medical Concepts will host a conference call today, May 25, 2021, at 4:30 p.m.
  • The Companys results for the quarter ended March 31, 2021 are not necessarily indicative of our operating results for any future periods.

ArthroCBD Shares Study's Findings for Arthritis Awareness Month

Retrieved on: 
Monday, May 24, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Skeletal disorders, Arthritis, Aging-associated diseases, Autoimmune diseases, Misconception, Arthritis Australia

There are common misconceptions around Arthritis, including what it's like to live with it.

Key Points: 
  • There are common misconceptions around Arthritis, including what it's like to live with it.
  • Throughout the month, ArthroCBD will share details of the findings as part of the "Celebrate Life Without Compromises" campaign.
  • A common myth is that arthritis only impacts the hands and knees.
  • Another misconception about living with arthritis is that it's just pain, and you should be able to work through it.

Treace Announces Interim Results from ALIGN3D™ Clinical Study at ACFAS 2021

Retrieved on: 
Wednesday, May 19, 2021
Skeletal disorders, Foot diseases, Arthropathies, Medical signs, Bunion, Valgus deformity, Valgus

ALIGN3D\xe2\x84\xa2 is a unique and comprehensive 5-year study, and we are pleased to report these positive interim results.

Key Points: 
  • ALIGN3D\xe2\x84\xa2 is a unique and comprehensive 5-year study, and we are pleased to report these positive interim results.
  • The primary effectiveness endpoint is radiographic recurrence of the hallux valgus deformity at 24 months follow up.
  • The study enrolled 173 patients, aged 14 to 58 years, at 7 clinical sites in the United States with 13 participating surgeons.
  • Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot.

Treace to Report First Quarter 2021 Financial Results on May 25, 2021

Retrieved on: 
Tuesday, May 18, 2021
Foot diseases, Skeletal disorders, Bunion

b'PONTE VEDRA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (\xe2\x80\x9cTreace\xe2\x80\x9d) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 25, 2021.

Key Points: 
  • b'PONTE VEDRA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (\xe2\x80\x9cTreace\xe2\x80\x9d) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 25, 2021.
  • Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.\nInvestors interested in listening to the conference call may do so by dialing (833) 730-3977 for domestic callers or (720) 405-2122 for international callers, followed by Conference ID: 1157038.
  • A live and archived webcast of the event will be available on the Company\xe2\x80\x99s investors relations website at https://investors.treace.com/ .\nTreace Medical Concepts is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities.
  • Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot.

Bioventus Senior Management to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, May 17, 2021
Skeletal disorders, Arthritis, Osteoarthritis, Medicine, Surgery

Both events are virtual conferences.\nPresentation materials from the events will be available in the investor relations section on the Bioventus website at https://www.bioventus.com prior to the start of each presentation.

Key Points: 
  • Both events are virtual conferences.\nPresentation materials from the events will be available in the investor relations section on the Bioventus website at https://www.bioventus.com prior to the start of each presentation.
  • The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing.
  • Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
  • Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.\n'